Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine.

ABSTRACT:

Objective

To assess the efficacy and safety of adding propranolol to topiramate in chronic migraine subjects inadequately controlled with topiramate alone.

Methods

This was a double-blind, placebo-controlled, randomized clinical trial conducted through the National Institute of Neurological Disorders and Stroke Clinical Research Collaboration, expected to randomize 250 chronic migraine subjects inadequately controlled (≥10 headaches/month) with topiramate (50-100 mg/day) to either propranolol LA (long acting) (240 mg/day) or placebo. Primary outcome was 28-day moderate to severe headache rate reduction at 6 months (weeks 16 to 24) compared with baseline (weeks -4 to 0).

Results

A planned interim analysis was performed after 48 sites randomized 171 subjects. The data a

SUBMITTER: Silberstein SD 

PROVIDER: S-EPMC3310312 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature